FAQs on liver transplant answered by an expert

By :

New Ebola Vaccine for Exposure Risk

When is a liver transplant ‘successful’? A liver transplant is a major operation which shows promising results in today’s times. A liver transplant is considered successful when the patient operated is given a discharge to go home without developing any complication of the surgery like an infection in the incision area, resistance to drugs given post-operation, internal bleeding or show symptoms of rejection of the organ. These are a few complications that can develop post a transplant, but if good care is taken and the surgeon is well-experienced chances of these errors are less. So, when a patient doesn’t develop any obvious complications, we can say that the transplant was successful. Here are four risk factors of non-alcoholic fatty liver disease. What is the rate of success of a liver transplant? This depends on a lot of factors – the hospital you choose, the doctor who performs the surgery, the patient’s immediate health status the quality of the cells transplanted, etc. The current liver transplant success rate at Medanta is 95% – which is among the highest in the world. When a transplant is not an option for people with the end-stage liver disease, how is it treated? There are a lot of cases where people suffering from end-stage liver diseases are not able to get treated or undergo a transplant. Especially, for people with advanced liver cancer, where cancer has spread beyond the liver into other organs or in case of liver failure, where the general condition of the patient is unsuitable, or their other body parts such as kidneys, heart and lungs are functioning sub-optimally which means they are weak and might not be able to withstand the trauma and stress of a major surgery. Who can donate? How does one ‘find’ a suitable donor? A suitable live liver donor is usually a close relative or spouse, 18-55 years of age, not obese and widely with matching blood groups. Here is a success story of a mother-son partial liver transplant. What are the new treatment options and surgeries available to treat liver diseases and ensure smooth transplant? While Hepatitis B, Hepatitis C is easily cured with effective drugs in the early stages, they often progress to decompensated cirrhosis and liver cancer later. Giving up alcohol can often control alcoholic fatty liver and even early cirrhosis. Non-alcoholic fatty liver disease or NAFLD is now the commonest liver disease. Besides controlling lifestyle, diabetes and hypercholesterolemia, are also factors that can induce NAFLD. However, there are new classes of drugs called FXR agonists that can reverse NAFLD and even early cirrhosis. Medical treatment – there are strong anti-viral drugs for Hepatitis C (sofosbuvir, velpatasvir) and hepatitis B (entecavir, tenofovir) that also works. What is the current situation of liver transplants in India and how can this be improved? Around 50,000 new cases of liver cancer and 2,50,000 cases of liver failure every year in India. 15-20 percent of these can be saved by timely transplants. However, only 1600 liver transplants are done in India annually, largely due to problems with donor availability/suitability and cost reasons. Improving donation rates after brain death could make it easy. Motivate more live donors by spreading awareness about keyhole, minimally invasive donor surgeries (done at Medanta) and the fact that live donation is totally safe – they go back to entirely normal physical, mental, emotional and sexual life after donation. How much is organ transplant a part of medical tourism in India? Medical tourism with organ donation is well developed in India. While 80 percent of all liver transplants at Medanta are for domestic and 20 percent for foreign patients, these figures at some other private hospitals are 50/50. One thing needs to be clarified – no Indian donors donate to foreigners. Expert : Dr Arvinder Singh Soin, Chairman Institute of Liver Transplantation and Regenerative Medicine, Medanta – The Medicity Source ' OHN #Health #transplant
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF Team

Basic facts about the French trial

Event Management Team

An interview on Postmarket Drug Safety: The View from FDA

PHAF Team

French clinical trial : 1 dead , 5 hospitalized

PHAF DIC Team

FAQs on liver transplant answered by an expert

Event Management Team

Patient Need Both an Opioid and Benzodiazepine? : Expert Commentary

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.